Janus kinase-inhibitors in the treatment of systemic lupus erythematosus
The pathogenesis of systemic lupus erythematosus(SLE)involves quantity and function abnormalities of cells and cytokines in both the innate and the acquired immune systems.The cytokine-mediated abnormal immune response has a common Janus kinase(JAK)/signal transducer and activator of transcription(STAT)signaling pathway,making the JAK/STAT path represent an important therapeutic target for SLE.JAK inhibitors,having been approved for rheumatoid arthritis and psoriasis,can inhibit the activation of immune cells and inflammation by regulating JAK/STAT signaling pathways.Animal models and clinical trials have shown the considerable potential of JAK inhibitors in treating SLE and lupus nephritis.This article reviews the role of JAK/STAT pathway in development of SLE,the mechanisms and clinical application of JAK inhibitors in treatment of SLE and lupus nephritis.
NETL
NSTL
万方数据
